EGF-like nucleic acids and polypeptides and uses thereof
AssigneeMillennium Pharmaceuticals, Inc.
InventorsSamantha J. Busfield, David P. Gearing
Life of this patent
Estimating the term…
Abstract
The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1,2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-α. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
Claims18
An isolated polypeptide comprising an amino acid sequence at least 95% identical to the full-length of the amino acid sequence of SEQ ID NO:
- 5 or 19, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98982, wherein the polypeptide stimulates growth and differentiation of keratinocytes.
A fusion protein comprising an Epidermal growth factor-Like Variant In Skin (ELVIS-2) polypeptide operably linked to a heterologous polypeptide, wherein the ELVIS-2 polypeptide comprises an amino acid sequence at least 95% identical to the full length of the amino acid sequence of SEQ ID NO:
- 5 or 19, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98982, and wherein the fusion protein stimulates growth and differentiation of keratinocytes.
A method for the detection of an Epidermal growth factor-Like Variant In Skin (ELVIS-2) polypeptide in a sample, wherein said ELVIS-2 polypeptide comprises an amino acid sequence that is at least 95% identical to the full length of the amino acid sequence of SEQ ID NO:
- 5 or 19, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98982, and wherein said ELVIS-2 polypeptide stimulates growth and differentiation of keratinocytes, comprising the steps of:
- a) combining said sample with an antibody or antibody fragment that binds to said ELVIS-2 polypeptide;
- and
- b) detecting a complex comprising said antibody or antibody fragment and said ELVIS-2 polypeptide,
- thereby detecting an ELVIS-2 polypeptide in said sample.
A method of identifying a compound that binds to an Epidermal growth factor-Like Variant In Skin (ELVIS-2) polypeptide, wherein said ELVIS-2 polypeptide comprises an amino acid sequence that is at least 95% identical to the full length of the amino acid sequence of SEQ ID NO:
- 5 or 19, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98982, and wherein said ELVIS-2 polypeptide stimulates growth and differentiation of keratinocytes, comprising the steps of:
- a) combining said ELVIS-2 polypeptide with a test compound;
- and
- b) detecting a complex comprising said ELVIS-2 polypeptide and said test compound;
- wherein said complex comprising said ELVIS-2 polypeptide and said test compound indicates that said test compound binds to said ELVIS-2 polypeptide.
A method of identifying a compound that modulates an activity of an Epidermal growth factor-Like Variant In Skin (ELVIS-2) polypeptide, wherein said ELVIS-2 polypeptide comprises an amino acid sequence that is at least 95% identical to the full length of the amino acid sequence of SEQ ID NO:
- 5 or 19, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98982, and wherein said ELVIS-2 polypeptide stimulates growth and differentiation of keratinocytes, comprising the steps of:
- a) combining said ELVIS-2 polypeptide with a test compound;
- and
- b) detecting the ability of said ELVIS-2 polypeptide to modulate the activity of a target molecule in the presence of said test compound and comparing said ability to the ability of said ELVIS-2 polypeptide to modulate the activity of the target molecule in the absence of said test compound;
- wherein a difference between the ability of said ELVIS-2 polypeptide to modulate the activity of a target molecule in the presence of said test compound and the ability of said ELVIS-2 polypeptide to modulate the activity of the target molecule in the absence of said test compound indicates that said test compound modulates said activity of said ELVIS-2 polypeptide.
Dependencies are inferred from the claim text.